Published in Women's Health Weekly, October 5th, 1998
The new intravenous product, trastuzumab (Herceptin), manufactured by Genentech, Inc., is approved for use alone for certain patients who have tried chemotherapy with little success or as a first-line treatment for metastatic disease when used in combination with paclitaxel (Taxol).
Herceptin is a monoclonal antibody bioengineered from part of a mouse antibody that is altered to closely resemble a human antibody. It binds to a protein called HER2 found on the surface of some normal cells and plays a role...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.